Quantifying non-specific interactions via liquid chromatography

Determinations of solute-cosolute interactions from chromatography have often resulted in problems, such as the “antibinding” (or a negative binding constant) between the solute and micelle in micellar liquid chromatography (MLC) or indeterminacy of salt-ligand binding strength in high-performance affinity chromatography (HPAC). This shows that the stoichiometric binding models adopted in many chromatographic analyses cannot capture the non-specific nature of solvation interactions. In contrast, an approach using statistical thermodynamics handles these complexities without such problems and directly links chromatographic data to, for example, solubility data via a universal framework based on Kirkwood-Buff integrals (KBI) of the radial distribution functions. The chromatographic measurements can now be interpreted within this universal theoretical framework that has been used to rationalize small solute solubility, biomolecular stability, binding, aggregation and gelation. In particular, KBI analysis identifies key solute-cosolute interactions, including excluded volume effects. We present (i) how KBI can be obtained directly from the cosolute concentration dependence of the distribution coefficient, (ii) how the classical binding model, when used solely as a fitting model, can yield the KBIs directly from the literature data, and (iii) how chromatography and solubility measurements can be compared in the unified theoretical framework provided via KBIs without any arbitrary assumptions about the stationary phase. To perform our own analyses on multiple datasets we have used an “app”. To aid readers’ understanding and to allow analyses of their own datasets, the app is provided with many datasets and is freely available on-line as an open-source resource

The long noncoding RNA THRIL regulates TNFalpha expression through its interaction with hnRNPL

Thousands of large intergenic noncoding RNAs (lincRNAs) have been identified in the mammalian genome, many of which have important roles in regulating a variety of biological processes. Here, we used a custom microarray to identify lincRNAs associated with activation of the innate immune response. A panel of 159 lincRNAs was found to be differentially expressed following innate activation of THP1 macrophages. Among them, linc1992 was shown to be expressed in many human tissues and was required for induction of TNFalpha expression. Linc1992 bound specifically to heterogenous nuclear ribonucleoprotein L (hnRNPL) and formed a functional linc1992-hnRNPL complex that regulated transcription of the TNFalpha gene by binding to its promoter. Transcriptome analysis revealed that linc1992 was required for expression of many immune-response genes, including other cytokines and transcriptional and posttranscriptional regulators of TNFalpha expression, and that knockdown of linc1992 caused dysregulation of these genes during innate activation of THP1 macrophages. Therefore, we named linc1992 THRIL (TNFalpha and hnRNPL related immunoregulatory LincRNA). Finally, THRIL expression was correlated with the severity of symptoms in patients with Kawasaki disease, an acute inflammatory disease of childhood. Collectively, our data provide evidence that lincRNAs and their binding proteins can regulate TNFalpha expression and may play important roles in the innate immune response and inflammatory diseases in humans

Large-area Si(Li) Detectors for X-ray Spectrometry and Particle Tracking for the GAPS Experiment

Large-area lithium-drifted silicon (Si(Li)) detectors, operable 150{\deg}C above liquid nitrogen temperature, have been developed for the General Antiparticle Spectrometer (GAPS) balloon mission and will form the first such system to operate in space. These 10 cm-diameter, 2.5 mm-thick multi-strip detectors have been verified in the lab to provide <4 keV FWHM energy resolution for X-rays as well as tracking capability for charged particles, while operating in conditions (~-40{\deg}C and ~1 Pa) achievable on a long-duration balloon mission with a large detector payload. These characteristics enable the GAPS silicon tracker system to identify cosmic antinuclei via a novel technique based on exotic atom formation, de-excitation, and annihilation. Production and large-scale calibration of ~1000 detectors has begun for the first GAPS flight, scheduled for late 2021. The detectors developed for GAPS may also have other applications, for example in heavy nuclei identification

Present developments in reaching an international consensus for a model-based approach to particle beam therapy

Particle beam therapy (PBT), including proton and carbon ion therapy, is an emerging innovative treatment for cancer patients. Due to the high cost of and limited access to treatment, meticulous selection of patients who would benefit most from PBT, when compared with standard X-ray therapy (XRT), is necessary. Due to the cost and labor involved in randomized controlled trials, the model-based approach (MBA) is used as an alternative means of establishing scientific evidence in medicine, and it can be improved continuously. Good databases and reasonable models are crucial for the reliability of this approach. The tumor control probability and normal tissue complication probability models are good illustrations of the advantages of PBT, but pre-existing NTCP models have been derived from historical patient treatments from the XRT era. This highlights the necessity of prospectively analyzing specific treatment-related toxicities in order to develop PBT-compatible models. An international consensus has been reached at the Global Institution for Collaborative Research and Education (GI-CoRE) joint symposium, concluding that a systematically developed model is required for model accuracy and performance. Six important steps that need to be observed in these considerations include patient selection, treatment planning, beam delivery, dose verification, response assessment, and data analysis. Advanced technologies in radiotherapy and computer science can be integrated to improve the efficacy of a treatment. Model validation and appropriately defined thresholds in a cost-effectiveness centered manner, together with quality assurance in the treatment planning, have to be achieved prior to clinical implementation